JAKAVI 20MG TABLET

Manufacturer : NOV-NOVARTIS INDIA LTD
Composition : RUXOLITINIB-20MG
Dose Form : TABLET
Description : JAKAVI 20MG TAB
Route Of Administration : ORAL
Pack : 10
Out of stock
SKU
JAK0008
₹225,200.00
Manufacturer : NOV-NOVARTIS INDIA LTD
Composition : RUXOLITINIB-20MG
Dose Form : TABLET
Description : JAKAVI 20MG TAB
Route Of Administration : ORAL
Pack : 10

Drug Ingredient Information

RUXOLITINIB-20MG

RUXOLITINIB

Information for patients
Drug Information Ruxolitinib trade names Jakafi and Jakavi is a drug for the treatment of intermediate or high-risk myelofibrosis, a type of bone marrow cancer.[2][3] It is also being investigated for the treatment of other types of cancer (such as lymphomas and pancreatic cancer),[4] for polycythemia vera,[4] for plaque psoriasis, and for alopecia areata.its molecular formula isc17h18n6
Drug Alert
Alert Treatment with Jakafi can cause thrombocytopenia, anemia and neutropenia.Severe neutropenia (ANC less than 0.5 X 109/L) was generally reversible by withholding Jakafi until recovery.
Before Consuming the Medicine
Avoid Drug no data
Drug Special Care no data
Drug Drug Interactions many number of major moderate and moinor interactions
Drug Pregnancy Interaction There are no data from the use of Jakavi in pregnant women.
Drug Breast feeding Interaction Jakavi must not be used during breast-feeding
Drug Machinery Interaction patients who experience dizziness after the intake of Jakavi should refrain from driving or using machines.
Drug More Information Ruxolitinib (INC424, INCB18424, trade names Jakafi and Jakavi, by Incyte Pharmaceuticals and Novartis) is a drug for the treatment of intermediate or high-risk myelofibrosis, a type of bone marrow cancer. It is also being investigated for the treatment of other types of cancer (such as lymphomas and pancreatic cancer),[4] for polycythemia vera] for plaque psoriasis, and for alopecia areata.
How to take the Medicine
Consumption Info Ruxolitinib (INC424, INCB18424, trade names Jakafi and Jakavi, by Incyte Pharmaceuticals and Novartis) is a drug for the treatment of intermediate or high-risk myelofibrosis, a type of bone marrow cancer. It is also being investigated for the treatment of other types of cancer (such as lymphomas and pancreatic cancer),[4] for polycythemia vera] for plaque psoriasis, and for alopecia areata.
Drug quanitty 15mg of medicine to be taken twice daily.
Drug Dose not applicable
Excess Drug Consumption There is no known antidote for overdoses with Jakavi. Single doses up to 200 mg have been given with acceptable acute tolerability. Higher than recommended repeat doses are associated with increased myelosuppression including leukopenia, anaemia and thrombocytopenia. Appropriate supportive treatment should be given. Haemodialysis is not expected to enhance the elimination of ruxolitinib.
Forgot Drug Consumption If a dose is missed, the patient should not take an additional dose, but should take the next usual prescribed dose.
Stop Drug Consumption no data
Possible Side Effects
General Information there are some possible side effcets associated with this drug
Common Drug Side Effects Myelosuppression Risk of Infection Myelofibrosis Symptom Exacerbation Following Interruption or Discontinuation of Treatment with Jakafi
Rare Drug Side Effects no data
Very Rare Drug Side Effects no data
Drug Side Effects Symptoms no data
How to Store the Medicine
How to Store the Medicine Do not store above 30°C.

Substitute Drugs

Write Your Own Review
You're reviewing:JAKAVI 20MG TABLET
Your Rating